OUR CEO, CRISTIANA VIGNOLI, AMONG THE WINNERS OF BFACTOR AWARD 2025 PROMOTED BY FONDAZIONE BELLISARIO

We are proud to announce that Cristiana Vignoli, CEO of Hemera, is among the winners of the 5th edition of the BFACTOR 2025 Award, promoted by the Marisa Bellisario Foundation under the High Patronage of the European Parliament, the Chamber of Deputies of the Italian Parliament, the Presidency of the Council of Ministers, the Ministry of Foreign Affairs, and the Ministry of International Cooperation.

The award celebrates women entrepreneurs who, with vision and courage, are driving sustainable innovation and creating value for the country’s development.

The recognition highlights Cristiana Vignoli’s leadership at Hemera, grounded in the strength of a multidisciplinary team of researchers, clinicians, and professionals united by a shared goal: turning research into care.

A result that makes us proud and reinforces our commitment to developing advanced cell therapies to heal the incurable.

STRENGTHENING INTERNATIONAL COLLABORATIONS FOR REMaST® DEVELOPMENT AND NEW THERAPEUTIC PERSPECTIVES

In the second half of 2025, Hemera further strengthened its international scientific collaborations to advance the validation of REMaST®, our cell therapy for nervous tissue regeneration. Partnerships have been established with leading international research centers to independently validate the neuroregenerative properties of our solution and to expand the foundations for future clinical trials, including new potential therapeutic applications.

In particular, the collaboration with the Center for Molecular Medicine at the University of Cologne (Germany) has confirmed the neuroregenerative properties of REMaST® and deepened the understanding of its interactions with neuronal cells, paving the way for possible applications in other neurodegenerative diseases.

At the same time, a collaboration has been launched with the Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg (Austria), aimed at studying the efficacy of REMaST® in experimental models of chronic spinal cord injury. Preliminary data confirm the therapy’s neuroregenerative potential also in this context and strengthen the foundation for extending its use to other nervous system disorders, opening new clinical perspectives.

PROGRESS IN CONSOLIDATING THE CLINICAL DEVELOPMENT OF REMaST® AND REGULATORY ALIGNMENT

In recent months, Hemera has continued to advance the consolidation of REMaST® development. The team has completed all necessary steps for the production of reagents in compliance with pharmaceutical-grade standards, involving specialized partners and submitting the protocol to the European Medicines Agency (EMA) for scientific advice.

This interaction with the regulatory authority provides valuable guidance to ensure that production processes are fully compliant and certifiable at the European level, bringing REMaST® closer to the first-in-human clinical trial phase.

In parallel, Hemera has developed strategic partnerships and launched fundraising initiatives aimed at supporting and accelerating the start of the clinical study — bringing this innovative therapy one step closer to real-world application for patients.